Predicting nerve damage from chemotherapy in cancer patients
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
This study is looking for a way to predict if patients will experience painful nerve issues from the cancer drug oxaliplatin by tracking their sensitivity to cold through a mobile app, making it easier to personalize treatments and help improve their comfort during chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Newventureiq, LLC NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project ID | NIH-10604018 on NIH RePORTER |
What this research studies
This research focuses on developing a biomarker to predict chemotherapy-induced peripheral neuropathy (CIPN), a painful side effect of the cancer drug oxaliplatin. By using a mobile health system, the study aims to collect and analyze patient-reported data on cold sensitivity, which may indicate the risk of developing CIPN. The approach is non-invasive and designed to be easily implemented, even in low-resource settings. If successful, this research could help tailor chemotherapy treatments to minimize nerve damage and improve patient quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients receiving oxaliplatin-based chemotherapy for colorectal cancer.
Not a fit: Patients not undergoing chemotherapy or those receiving treatments other than oxaliplatin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of painful nerve damage in cancer patients undergoing chemotherapy.
How similar studies have performed: Preliminary studies using similar predictive methods have shown promising results, indicating potential for success in this approach.
Where this research is happening
St. Louis, UNITED STATES
- Newventureiq, LLC — St. Louis, United States (Active)
Researchers
- Principal investigator: Haroutounian, Simon — Newventureiq, LLC
- Study coordinator: Haroutounian, Simon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.